Post-authorization safety study of Clottafact®, a triply secured fibrinogen concentrate in congenital afibrinogenemia. A prospective observational study-Reference-Cited by-同舟云学术

Post-authorization safety study of Clottafact®, a triply secured fibrinogen concentrate in congenital afibrinogenemia. A prospective observational study

Published:2016-09-01 Issue:4 Volume:111 Page:383-390
ISSN:0042-9007
Container-title:Vox Sanguinis
language:en
Short-container-title:Vox Sang

Author:

Négrier C.¹,Rothschild C.²,Borg J.-Y.³,Lambert T.⁴,Claeyssens S.⁵,Sanhes L.⁶,Stieltjes N.⁷,Bertrand A.⁸,André M.-H.⁸,Sié P.⁹,Gruel Y.¹⁰,Tellier Z.⁸

Affiliation:

1. Edouard Herriot Hospital; Lyon France

2. Hemophilia Centre; Necker Enfants Malades University Hospital - APHP Paris; Paris France

3. Charles Nicolle Hospital; Rouen France

4. Bicêtre Hospital; Kremlin Bicêtre France

5. Purpan Hospital; Toulouse France

6. Saint-Jean Hospital; Perpignan France

7. Cochin Hospital; Paris France

8. Medical Affairs; LFB Biomédicaments; Les Ulis France

9. Rangueil Hospital; Toulouse France

10. Trousseau Hospital; Tours France

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/vox.12424/fullpdf

Reference20 articles.

1. Fibrinogen and fibrin structure and functions;Mosesson;J Thromb Haemost,2005

2. Pharmacokinetics and pharmacodynamics of a new highly secured fibrinogen concentrate;Negrier;J Thromb Haemost,2008

3. The rare coagulation disorders-review with guidelines for management from the United Kingdom Haemophilia Centre Doctors’ Organisation;Bolton-Maggs;Haemophilia,2004

4. Rare coagulation disorders;Peyvandi;Thromb Haemost,1999

5. Congenital fibrinogen disorders: an update;Moerloose;Semin Thromb Hemost,2013

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. One Hundred Years of Congenital Fibrinogen Disorders;Seminars in Thrombosis and Hemostasis;2022-09-02

2. Efficacy and safety of fibrinogen concentrate for perioperative prophylaxis of bleeding in adult, adolescent, and pediatric patients with congenital fibrinogen deficiency: FORMA ‐02 and FORMA ‐04 clinical trials;Transfusion;2022-08-06

3. Heterogeneity of congenital afibrinogenemia, from epidemiology to clinical consequences and management;Blood Reviews;2021-07

4. Clinical phenotype, fibrinogen supplementation, and health-related quality of life in patients with afibrinogenemia;Blood;2021-06-03

5. Congenital Fibrinogen Deficiency in India and Role of Human Fibrinogen Concentrate;Acta Haematologica;2021